Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

No clear-cut evidence of vedolizumab effect in retrospective study of primary sclerosing cholangitis

Key clinical point: In contrast to some case reports and case series, a larger retrospective study has provided no clear-cut evidence of biochemical response to vedolizumab in patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD).

Major finding: One in five patients had a drop in alkaline phosphatase (ALP) of at least 20% from baseline, though overall, median ALP increased from 1.53 to 1.64 times the upper limit of normal.

Study details: Retrospective study including 102 patients with PSC-IBD who received at least three doses of vedolizumab.

Disclosures: The research was supported by the Birmingham National Institute for Health Research (NIHR) Biomedical Research Centre in the United Kingdom. Authors of the report provided disclosures related to Takeda, AbbVie, Dr. Falk Pharma, Intercept, MSD, Janssen, Vifor, Gilead, and Novartis, among others.

Citation:

Lynch KD et al. Clin Gastroenterol Hepatol. 2019 May 14. doi: 10.1016/j.cgh.2019.05.013.